Foresee Pharmaceuticals Announces First Patient Dosed in the Casppian, Phase 3 Clinical Trial of Leuprolide (FP-001) injectable emulsion, 42 mg for the treatment of Central Precocious Puberty patients.

By /

Foresee Pharmaceuticals, announces that the first patient has been dosed in the Casppian Phase 3 registration study.

Scroll to Top